Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo
Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to determine the clinical effects of doxycycline 40 mg (30 mg
immediate release and 10 mg delayed release beads) capsules (Oracea®) as compared to placebo
in the skin of adults with papulopustular rosacea and to identify a correlation, if any, with
rosacea-related inflammatory markers.